Movement Alert｜Vertex Pharmaceuticals Rises 9.21% in Regular Trading, Q2 Earnings Beat Expectations with Full-Year Guidance Raised

Market Focus08-10 21:31

On August 10, Vertex Pharmaceuticals rose 9.21% in regular trading, trading at $544.2/share, with turnover of $159 million. The surge was driven by the company's strong Q2 earnings report and an upward revision to full-year revenue guidance.

Vertex reported Q2 revenue of $3.33 billion, exceeding the consensus estimate of $3.23 billion and representing a 12.5% year-over-year increase. Adjusted EPS came in at $4.73, up 4.6% from the prior year. The company raised its full-year revenue guidance to $13.1 billion-$13.2 billion, up from the prior range of $12.95 billion-$13.1 billion and above the Street estimate of $13.06 billion. Following the results, multiple institutions lifted their price targets: Cantor Fitzgerald raised to $595, Rothschild to $580, and Goldman Sachs had previously adjusted to $652.

Additionally, the approximately $10 billion acquisition of Crinetics Pharmaceuticals is expected to close this quarter, adding an endocrinology business pillar with an estimated $5 billion peak sales opportunity to Vertex's portfolio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199656530?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199656530","market":"us","top_or_hot":-1,"title":"Movement Alert｜Vertex Pharmaceuticals Rises 9.21% in Regular Trading, Q2 Earnings Beat Expectations with Full-Year Guidance Raised","media":"Market Focus","content":"<p><p>On August 10, Vertex Pharmaceuticals rose 9.21% in regular trading, trading at $544.2/share, with turnover of $159 million. The surge was driven by the company's strong Q2 earnings report and an upward revision to full-year revenue guidance.</p><p>Vertex reported Q2 revenue of $3.33 billion, exceeding the consensus estimate of $3.23 billion and representing a 12.5% year-over-year increase. Adjusted EPS came in at $4.73, up 4.6% from the prior year. The company raised its full-year revenue guidance to $13.1 billion-$13.2 billion, up from the prior range of $12.95 billion-$13.1 billion and above the Street estimate of $13.06 billion. Following the results, multiple institutions lifted their price targets: Cantor Fitzgerald raised to $595, Rothschild to $580, and Goldman Sachs had previously adjusted to $652.</p><p>Additionally, the approximately $10 billion acquisition of Crinetics Pharmaceuticals is expected to close this quarter, adding an endocrinology business pillar with an estimated $5 billion peak sales opportunity to Vertex's portfolio.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Vertex Pharmaceuticals Rises 9.21% in Regular Trading, Q2 Earnings Beat Expectations with Full-Year Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Vertex Pharmaceuticals Rises 9.21% in Regular Trading, Q2 Earnings Beat Expectations with Full-Year Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-10 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 10, Vertex Pharmaceuticals rose 9.21% in regular trading, trading at $544.2/share, with turnover of $159 million. The surge was driven by the company's strong Q2 earnings report and an upward revision to full-year revenue guidance.</p><p>Vertex reported Q2 revenue of $3.33 billion, exceeding the consensus estimate of $3.23 billion and representing a 12.5% year-over-year increase. Adjusted EPS came in at $4.73, up 4.6% from the prior year. The company raised its full-year revenue guidance to $13.1 billion-$13.2 billion, up from the prior range of $12.95 billion-$13.1 billion and above the Street estimate of $13.06 billion. Following the results, multiple institutions lifted their price targets: Cantor Fitzgerald raised to $595, Rothschild to $580, and Goldman Sachs had previously adjusted to $652.</p><p>Additionally, the approximately $10 billion acquisition of Crinetics Pharmaceuticals is expected to close this quarter, adding an endocrinology business pillar with an estimated $5 billion peak sales opportunity to Vertex's portfolio.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRTX","symbol_name":"福泰制药","start_time":0,"source_url":"","article_id":"1199656530","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199656530","pubTimestamp":1786368684,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 10, Vertex Pharmaceuticals rose 9.21% in regular trading, trading at $544.2/share, with turnover of $159 million. The surge was driven by the company's strong Q2 earnings report and an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRTX":"福泰制药"},"translate_title":"走势提醒|Vertex Pharmaceuticals 常规交易中上涨 9.21%，第二季度盈利超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":1},"content_text":"On August 10, Vertex Pharmaceuticals rose 9.21% in regular trading, trading at $544.2/share, with turnover of $159 million. The surge was driven by the company's strong Q2 earnings report and an upward revision to full-year revenue guidance.Vertex reported Q2 revenue of $3.33 billion, exceeding the consensus estimate of $3.23 billion and representing a 12.5% year-over-year increase. Adjusted EPS came in at $4.73, up 4.6% from the prior year. The company raised its full-year revenue guidance to $13.1 billion-$13.2 billion, up from the prior range of $12.95 billion-$13.1 billion and above the Street estimate of $13.06 billion. Following the results, multiple institutions lifted their price targets: Cantor Fitzgerald raised to $595, Rothschild to $580, and Goldman Sachs had previously adjusted to $652.Additionally, the approximately $10 billion acquisition of Crinetics Pharmaceuticals is expected to close this quarter, adding an endocrinology business pillar with an estimated $5 billion peak sales opportunity to Vertex's portfolio.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199656530","isCrawlerRequest":true}